Clinical Research Atlanta

Clinical Research Atlanta maintains performance metrics on a quarterly basis. In addition to metrics by therapeutic area, CRA is proud of some additional perfomance measures outlined below.

• Regulatory and Contract Turnaround:  Less than one week
• First Subject In from Contract Date:  1-2 days
• eCRF data entry:  within 24 hours of patient visit and same day for queries generated by monitor visit.

RESPIRATORY

(Includes Seasonal and Perennial Allergic Rhinitis, Asthma, COPD and Cold/Flu)

• Number of Trials: 35
• Screened Patients that Randomize: 74%
• Contracted Enrollment that Complete Trial: 104%
• Randomized Patients that Early Terminate: 8%
• Randomized Patients that Complete Trial: 86%
• Enrollment Rate: 121%

GASTROENTEROLOGY

(including GERD, Chronic Constipation and IBS)

• Number of Trials: 29
• Screened Patients that Randomize: 78%
• Contracted Enrollment that Complete Trial: 75%
• Randomized Patients that Early Terminate: 51%
• Randomized Patients that Complete Trial: 61%
• Enrollment Rate: 123%

ORTHOPAEDIC

 (including Osteoarthritis of Knee and Tendonitis)

• Number of Trials: 4
• Screened Patients that Randomize: 71%
• Contracted Enrollment that Complete Trial: 112%
• Randomized Patients that Early Terminate: 4%
• Randomized Patients that Complete Trial: 96%
• Enrollment Rate: 117%

METABOLIC

(including Obesity, Gout and Type II Diabetes)

• Number of Trials: 6
• Screened Patients that Randomize: 70%
• Contracted Enrollment that Complete Trial: 52%
• Randomized Patients that Early Terminate: 29%
• Randomized Patients that Complete Trial: 47%
• Enrollment Rate: 109%

VACCINE

• Number of Trials: 11
• Screened Patients that Randomize: 96%
• Contracted Enrollment that Complete Trial: 105%
• Randomized Patients that Early Terminate: 2%
• Randomized Patients that Complete Trial: 98%
• Enrollment Rate: 107%

PEDIATRIC TRIALS

 (including Seasonal and Perennial Allergic Rhinitis and Normal Healthy)

• Number of Trials: 6
• Screened Patients that Randomize: 74%
• Contracted Enrollment that Complete Trial: 89%
• Randomized Patients that Early Terminate: 23%
• Randomized Patients that Complete Trial: 77%
• Enrollment Rate: 115%

OVERACTIVE BLADDER

• Number of Trials: 1
• Screened Patients that Randomize: 43%
• Contracted Enrollment that Complete Trial: 225%
• Randomized Patients that Early Terminate: 10%
• Randomized Patients that Complete Trial: 90%
• Enrollment Rate: 250%

TINEA PEDIS

• Number of Trials: 1
• Screened Patients that Randomize: 75%
• Contracted Enrollment that Complete Trial: 30%
• Randomized Patients that Early Terminate: 0%
• Randomized Patients that Complete Trial: 67%
• Enrollment Rate: 45%

HYPERTENSION

• Number of Trials: 4
• Screened Patients that Randomize: 46%
• Contracted Enrollment that Complete Trial: 104%
• Randomized Patients that Early Terminate: 3%
• Randomized Patients that Complete Trial: 107%
• Enrollment Rate: 107%

MIGRAINE

• Number of Trials: 2
• Screened Patients that Randomize: 37%
• Contracted Enrollment that Complete Trial: 53%
• Randomized Patients that Early Terminate: 36%
• Randomized Patients that Complete Trial: 71%
• Enrollment Rate: 74%

NORMAL HEALTHY

• Number of Trials: 2
• Screened Patients that Randomize: 100%
• Contracted Enrollment that Complete Trial: 145%
• Randomized Patients that Early Terminate: 18%
• Randomized Patients that Complete Trial: 82%
• Enrollment Rate: 178%